Tocqueville Asset Management L.P. purchased a new position in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 26,175 shares of the biotechnology company’s stock, valued at approximately $311,000.
Other large investors also recently bought and sold shares of the company. BNP Paribas Arbitrage SA bought a new position in shares of Adaptimmune Therapeutics in the second quarter valued at $122,000. BB&T Securities LLC bought a new position in shares of Adaptimmune Therapeutics in the second quarter valued at $128,000. Raymond James Financial Services Advisors Inc. lifted its stake in shares of Adaptimmune Therapeutics by 70.0% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 31,951 shares of the biotechnology company’s stock valued at $379,000 after buying an additional 13,151 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Adaptimmune Therapeutics in the first quarter valued at $168,000. Finally, Trexquant Investment LP bought a new position in shares of Adaptimmune Therapeutics in the second quarter valued at $178,000. Institutional investors and hedge funds own 59.32% of the company’s stock.
A number of research analysts have weighed in on the stock. BidaskClub raised shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, September 29th. ValuEngine raised shares of Adaptimmune Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Monday, July 2nd. Cowen reissued a “buy” rating on shares of Adaptimmune Therapeutics in a research report on Wednesday, July 18th. TheStreet lowered shares of Adaptimmune Therapeutics from a “c-” rating to a “d+” rating in a research report on Monday, July 16th. Finally, Zacks Investment Research lowered shares of Adaptimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $19.33.
Shares of ADAP traded down $0.26 during trading hours on Friday, reaching $13.90. 347,784 shares of the stock traded hands, compared to its average volume of 495,012. Adaptimmune Therapeutics PLC – has a 52 week low of $6.60 and a 52 week high of $14.63. The firm has a market capitalization of $1.28 billion, a P/E ratio of -17.38 and a beta of 1.06.
Adaptimmune Therapeutics (NASDAQ:ADAP) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.20). Adaptimmune Therapeutics had a negative return on equity of 47.22% and a negative net margin of 191.14%. The company had revenue of $9.04 million for the quarter, compared to analysts’ expectations of $7.76 million. As a group, analysts predict that Adaptimmune Therapeutics PLC – will post -1.02 earnings per share for the current year.
In related news, Director Ali Behbahani acquired 12,000,000 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The stock was acquired at an average price of $1.67 per share, for a total transaction of $20,040,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Gwendolyn Knowlt Binder-Scholl sold 25,000 shares of Adaptimmune Therapeutics stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $13.79, for a total transaction of $344,750.00. The disclosure for this sale can be found here. Company insiders own 26.47% of the company’s stock.
About Adaptimmune Therapeutics
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its platform enables in identifying cancer targets; finding and genetically engineering T-cell receptors (TCR); and producing TCR therapeutic candidates for administration to patients.
Featured Story: Should I invest in “strong buy” stocks?
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.